Night Hypoxia Tied to Progression of Peds Liver Disease

Share this content:
Night Hypoxia Tied to Progression of Peds Liver Disease
Night Hypoxia Tied to Progression of Peds Liver Disease

MONDAY, Aug. 8, 2016 (HealthDay News) -- Obstructive sleep apnea (OSA)/hypoxia is associated with progression of nonalcoholic steatohepatitis (NASH) in pediatric patients with nonalcoholic fatty liver disease (NAFLD), according to a study published online Aug. 5 in the Journal of Hepatology.

Shikha S. Sundaram, M.D., from the Children's Hospital Colorado in Aurora, and colleagues studied 36 adolescents with biopsy proven NAFLD and 14 lean controls. Participants underwent polysomnograms, liver histology scoring, laboratory testing, urine F(2)-isoprostanes, and 4-hydroxynonenal (4HNE) liver immunohistochemistry.

The researchers found that the OSA/hypoxia group (69 percent of NAFLD subjects) had more severe fibrosis than those without OSA/hypoxia (P = 0.03). There were correlations for higher F(2)-isoprostanes with apnea/hypoxia index and percent of time O2 saturation (SaO2) <90 percent, and an inverse correlation with SaO2 nadir. Subjects with the greatest 4HNE staining had the most severe OSA/hypoxia (P = 0.03). There were correlations for increasing F(2)-isoprostanes and 4HNE hepatic staining with worsening steatosis (P = 0.04 and 0.007, respectively). Subjects with definite NASH had greater oxidative stress compared to those with borderline/not NASH.

"These data support the role of nocturnal hypoxia as a trigger for localized hepatic oxidative stress, an important factor associated with the progression of NASH and hepatic fibrosis in obese pediatric patients," the authors write.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »